Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.5K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

282
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
282
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

212
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
212
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

459
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
459
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

16
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
16
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

21
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
21

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Liver Transplantation for HBV-Related Disease in France: NUC Type Before LT Is Associated With Patient Survival.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Age and sex disparities in drug shortage impacts: a 10-year nationwide study in France.

European journal of public health·2026
Same author

[Assessing the risk-benefit balance of medicines: Some lessons from Covid-19].

Medecine sciences : M/S·2026
Same author

Graft and Patient Survival After Liver Transplantation for Primary Sclerosing Cholangitis: A French National Cohort Study.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Treprostinil Iontophoresis in Diabetic Foot Ulcers: A Single Ascending Dose Safety Study.

Fundamental & clinical pharmacology·2025
Same author

Risk of major congenital anomalies and beta-blockers: A comparative study from the EFEMERIS database.

British journal of clinical pharmacology·2025

Related Experiment Video

Updated: Feb 17, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.8K

Atorvastatin-Associated Liver Injury: Outcome After Statin Rechallenge.

Blandine Bertin1, Valentine Lacotte1, Jean-Luc Cracowski2,3

  • 1Pharmacovigilance Center, Hospital University Pharmacotoxicology Department, Hospices Civils de Lyon, Lyon, France.

Fundamental & Clinical Pharmacology
|February 15, 2026
PubMed
Summary

Statin rechallenge after atorvastatin liver injury frequently causes recurrence. However, hydrophilic statins like rosuvastatin or pravastatin appear safer for reintroduction, with lower recurrence risks.

Keywords:
adverse drug reactiondrug‐induced liver injuryhydroxymethylglutaryl‐CoArecurrencereductase inhibitorsretreatment

More Related Videos

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.7K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.0K

Related Experiment Videos

Last Updated: Feb 17, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.8K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.7K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.0K

Area of Science:

  • Pharmacology
  • Hepatology
  • Drug Safety

Background:

  • Statin-induced liver injury (DILI) is common but typically mild.
  • Data on the safety of statin rechallenge after atorvastatin-induced liver injury is limited.

Purpose of the Study:

  • To investigate the safety and recurrence rates of statin rechallenge following atorvastatin-induced liver injury.
  • To identify statins with a potentially lower risk of recurrence.

Main Methods:

  • Retrospective analysis of cases from the French pharmacovigilance database.
  • Inclusion of patients with documented atorvastatin or alternative statin reintroduction and at least 2 weeks of follow-up.
  • Categorization of liver injury patterns (cholestatic, cytolytic, mixed) and severity grading.

Main Results:

  • Twenty-six cases of atorvastatin DILI with subsequent statin reintroduction were analyzed.
  • Recurrence of liver injury was observed in 12 of 16 patients rechallenged with atorvastatin (shorter time to onset).
  • Two of ten patients experienced recurrence with alternative statins (rosuvastatin, simvastatin); hydrophilic statins (rosuvastatin, pravastatin) showed no recurrence in small cohorts.

Conclusions:

  • Drug-induced liver injury frequently recurs upon atorvastatin rechallenge.
  • Hydrophilic statins, specifically rosuvastatin and pravastatin, may be better tolerated upon rechallenge.
  • Further research with larger cohorts is needed to confirm the safety of hydrophilic statins after statin-induced liver injury.